# Methuselah Medical Technology(Shanghai) Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/methuselah-medical-technology-shanghai-co

- Industry: Food
- Headquarters: Shanghai, China
- Website: www.mn969.com
- Total disclosed funding: $42M
- Latest round: Series B (Aug 4, 2025)
- Investors on record: 8

## About

Based in Shanghai, China, and founded in 2012, Methuselah Medical Technology(Shanghai) Co., Ltd operates as a medical nutrition food developer focusing on the R&D, production, and sales of medical nutrition products. It has partnerships with Babytree, Changhai Hospital, Xinhua Hospital, etc. The company's chairman and general manager, Liming Tang, is a national registered dietitian and practicing physician, holds a bachelor's degree in medicine from Zhengzhou University School of Medicine and an EMBA degree from Fudan University, and is the deputy secretary general of the Nutrition and Rehabilitation Committee of the China Society of Rehabilitation Medicine. Its products have been stationed in more than 500 hospitals in China, with C-sales of over 100 million yuan. In August 2025, Methuselah Medical Technology(Shanghai) Co., Ltd raised a series B+ funding led by new investors Bailian Investment and Confitop Capital with participation from returning investors HighLight Capitala and Hongsheng Capital. The company has produced four series of medical nutrition products, including the special medical foods series, nutrition fortification series, low GI series, energy-controlled foods series, and fatty-controlled foods series. Its product types include powders, liquids, cookies, food bars, noodles, bakery, and konjac products. The company has produced four series of medical nutrition products, including the special medical foods series, nutrition fortification series, low GI series, energy-controlled foods series, and fatty-controlled foods series. Its product types include powders, liquids, cookies, food bars, noodles, bakery, and konjac products. The company’s revenue is generated by providing medical nutrition products. The fund raised in series B+ round of financing will be mainly used to strengthen continuous R&D investment in core products and advance clinical trials.

## Funding rounds

- Series B, Aug 4, 2025 — HighLight Capital, Hongsheng Junhao Investment, Confitop Capital, Bailian Investment
- Series B, Feb 19, 2025, $28M — China International Capital Corporation, HighLight Capital, Hongsheng Junhao Investment, Borchid Capital, Frees Fund
- Series A, Apr 18, 2023, $15M — Frees Fund, Jinding Capital

## Investors

- Frees Fund (https://capitalatlas.ai/funds/frees-fund) — Series A, Series B
- Jinding Capital (https://capitalatlas.ai/funds/jinding-capital) — Series A
- China International Capital Corporation (https://capitalatlas.ai/funds/china-international-capital-corporation) — Series B
- HighLight Capital (https://capitalatlas.ai/funds/highlight-capital) — Series B
- Hongsheng Junhao Investment (https://capitalatlas.ai/funds/hongsheng-junhao-investment) — Series B
- Borchid Capital (https://capitalatlas.ai/funds/borchid-capital) — Series B
- Confitop Capital (https://capitalatlas.ai/funds/confitop-capital) — Series B
- Bailian Investment — Series B